Good decisions require good information

Find hidden gems and smart strategies from top experts when you join Seeking Alpha.

RARE Ultragenyx Pharmaceutical Inc.
Valuation Measures

$40.141.49 (+3.86%)4:00 PM 05/31/24
NASDAQ | $USD | Post-Market: $40.14 5:04 PM

Valuation Metrics

RARE Valuation Grade

Type
Grade
RARE
Sector Median
% Diff. to Sector
RARE 5Y Avg.
% Diff. to 5Y Avg.
P/E Non-GAAP (TTM)
-Rating: Not Covered
NM
19.70
NM
-
-
P/E Non-GAAP (FWD)
-Rating: Not Covered
NM
19.62
NM
-
-
P/E GAAP (TTM)
NM
32.22
NM
-
-
P/E GAAP (FWD)
NM
27.03
NM
-
-
PEG GAAP (TTM)
-
0.95
-
-
-
PEG Non-GAAP (FWD)
-
1.90
-
-
-
EV / Sales (TTM)
8.36
3.75
122.74%
16.79
-50.24%
EV / Sales (FWD)
7.23
3.47
108.51%
13.66
-47.12%
EV / EBITDA (TTM)
NM
15.63
NM
-
-
EV / EBITDA (FWD)
NM
13.01
NM
-
-
EV / EBIT (TTM)
NM
22.68
NM
-
-
EV / EBIT (FWD)
NM
16.14
NM
-
-
Price / Sales (TTM)
6.99
3.64
91.83%
19.04
-63.31%
Price / Sales (FWD)
6.52
3.63
79.46%
16.40
-60.28%
Price / Book (TTM)
23.76
2.47
861.31%
13.57
75.13%
Price / Book (FWD)
7.13
2.72
162.18%
6.72
6.07%
Price / Cash Flow (TTM)
NM
18.34
NM
-
-
Price / Cash Flow (FWD)
NM
15.27
NM
-
-
Dividend Yield (TTM)
-
1.46%
-
-
-

Go Premium to see Valuation Grades on RARE

*Grades are relative to the Health Care sector

**NM signifies a non meaningful value. A dash signifies the data is not available.

RARE Price/Earnings (P/E) Ratio

View Ultragenyx Pharmaceutical Inc. (RARE) current and estimated P/E ratio data provided by Seeking Alpha.

Price/Earnings Ratio

Consensus EPS Estimate Growth Rate

Capital Structure

People Also Follow